Structure via PubChem · Public domain (PubChem)
laquinimod
Sign in to saveAlso known as 5-chloro-4-hydroxy-1-methyl-2-oxo-N-ethyl-N-phenyl-1,2-dihydroquinoline-3-carboxamide
Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.
Chemical data
- Formula
- C19H17ClN2O3
- Molecular weight
- 356.8 g/mol
- IUPAC name
- 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
- SMILES
- CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O
- InChIKey
- GKWPCEFFIHSJOE-UHFFFAOYSA-N
- XLogP
- 3.7
- Polar surface area
- 60.9 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- Crohn's disease, relapsing-remitting multiple sclerosis, lupus nephritis, primary progressive multiple sclerosis
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 356.092770084
Show 2 more facts
- chemical formula
- C₁₉H₁₇ClN₂O₃
- canonical SMILES
- CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
3 sectionsContents
- See also
- References
- External links
Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.
Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide.
Excerpted from Wikipedia’s “laquinimod” article, available under the CC BY-SA 4.0 licence.